Close Menu

equity investment

The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.

UK-based Abcam has also taken an undisclosed equity stake in BrickBio, located in Boston, and will work with the company to further develop its platform.

The Swiss startup plans to use the funding to support the development of genomic analysis software based on the new MPEG-G compression standard.

Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.

The Australian molecular diagnostics firm will use the funds to accelerate commercial expansion in North America and global markets.

With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.

The firms will collaborate to develop Synlogics pipeline of synthetic medicines using Ginkgo's microbial programming and optimization platform.

Variantyx, a 2014 spinout from Tel Aviv University that is based in Framingham, Massachusetts, provides clinical genomic testing for screening and rare disease diagnostics.

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

The new funding brings the Series B total to £23.3 million for the British clinical decision support technology developer.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.